The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of dabrafenib and trametinib in patients with BRAFV600E/R or non-BRAFV600 mutated advanced solid tumors: Results from the BELIEVE trial (NCCH1901).
 
Makoto Tahara
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; MSD; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Genmab; Janssen; Lilly; MSD; Nanobiotix; Nektar; Ono Pharmaceutical; Pfizer; Rakuten Medical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Rakuten Medical (Inst)
 
Tatsunori Shimoi
No Relationships to Disclose
 
Satoshi Nishiwaki
No Relationships to Disclose
 
Shota Tanaka
Honoraria - Chugai Pharma; Daiichi-Sankyo Co., Ltd.; Eisai; Novocure
Research Funding - Eisai; Ono Pharmaceutical; Sumitomo Dainippon Pharma co., Ltd.; Takeda Science Foundation
Patents, Royalties, Other Intellectual Property - P2019-095102; PCT/JP2020/019814
 
Eishi Baba
Honoraria - Chugai Pharma; Daiichi Sankyo; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Manabu Muto
Speakers' Bureau - Canon Medical System; Chugai Pharma; Daiichi Sankyo/Lilly; Illumina; Incyte Japan; Merck; MSD; Novartis; Olympus; Ono Pharmaceutical; Shionogi
Research Funding - Canon Medical System; Chugai Pharma; H.U. Group Holdings; Meiji Seika Kaisha; NTT; NTT Data; Taiho Pharmaceutical
 
Ichiro Kinoshita
Honoraria - AstraZeneca/Daiichi Sankyo; Bayer; Chugai Pharma; MSD; Takeda
 
Daisuke Sakai
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo/UCB Japan
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo; Eisai (Inst); Incyte (Inst); Lilly Japan; Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Masahiro Tabata
No Relationships to Disclose
 
Hideyuki Hayashi
No Relationships to Disclose
 
Chikashi Ishioka
Honoraria - Asahi Kasei; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Incyte Japan; Kyowa Kirin International; Lilly Japan; M3; M3; Merck; MSD; Nihon Servier; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.
Research Funding - Asahi Kasei (Inst); Ascent Pharmahealth (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Hitachi (Inst); Incyte (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Merck (Inst); MSD (Inst); Nihonkayaku (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka; Riken Genesis (Inst); Taiho Pharmaceutical (Inst); Tsumura & Co. (Inst)
 
Nobuaki Mamesaya
Honoraria - AstraZeneca Japan; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Noboru Yamamoto
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Ono Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Healios; Merck; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst)